Wikipedia -WSS

Wikipedia

author：leisure time 2025-10-02 11:08:12 - browse：22584

Amylyx founders — Justin Klee, left, and Joshua Cohen, both co-founders and co-CEO's of Amylyx Pharmaceuticals. Kayana Szymczak for STAT

The Food and Drug Administration has reversed an internal decision and will now review an experimental treatment for amyotrophic lateral sclerosis — a victory for ALS patients and advocates who have been pressuring regulators to act with more urgency against the fatal, neurodegenerative disease.

Amylyx Pharmaceuticals, a Cambridge, Mass.-based drug maker, said Wednesday that it will submit an application for its ALS treatment, called AMX0035, “in the coming months.”

The filing will be based largely on a single clinical trial of AMX0035 completed one year ago that showed a significant slowing of disease progression in patients with ALS. It’s the same study that FDA officials told Amylyx last April was encouraging, but not convincing enough to review for approval on its own. The company was told by FDA staff to conduct another study, gather more positive data, and then file for approval.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： How I ended up pumping milk in a bathroom stall at JPM 2024

hotspot

WSS

FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

FDA seeking to stop procedures at two unregulated stem cell clinics

Readout LOUD podcast: FTC v. biotech, future of Pfizer and Vertex

Biden administration sends mixed signals on US soldier who crossed into North Korea

Manchin plays down potential 3rd

Search resumes for 2 missing children washed away with mom in deadly Pennsylvania flash flood

knowledge

Wikipedia

explore

What does generative AI mean for health care? We asked experts

Readout LOUD podcast: 2023 in review, and a look at biotech in 2024

Hepatitis C has a cure — but many Americans still lack access to it

Vivek Ramaswamy, who's embraced Trump on the campaign trail, condemned him after Jan. 6

The cancer drug shortage isn’t new — and neither are the solutions

A strong 6.5

Hollywood unions extend contract negotiations for actors

Fauci’s Covid grilling leads GOP to weigh foreign research rules

Novavax promises a turnaround & Lilly roils the obesity market

Lack of darker skin in textbooks, journals harms patients of color

focus

FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

The nurse manager staffing crisis is hurting patients

BridgeBio heart drug succeeds in pivotal study

US soldier in North Korean custody after crossing DMZ line

FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

Ford plant in Missouri shuts down over 'possible threat,' sheriff's office says

hotspot

hotspot

hotspot

focus